Listen

Goals

  • To unravel the underlying mechanisms of the tumor immune attack and resistance to understand the tumor micro-environment at a (sub)cellular level and to adjust the function of immune cells to improve tumor killing and circumvent tumor-induced resistance. 
  • To improve the use of currently available immunotherapies by developing biomarkers to select patients to improve efficacy and avoid toxicity and by investigating different schemes (lower dose/shorter duration) to reduce toxicity and costs. 
  • To develop new immunotherapeutic strategies for clinical application by initiating preclinical in vitro and animal experiments to develop new immunotherapeutic strategies and by starting phase I / II clinical trials at a new multidisciplinary phase I unit (CANTO).


go to main content
Research Research programs Cancer immunotherapy:

Our mission

We aim to unravel the underlying mechanisms of tumor-immune attack and resistance in a wide variety of cancer types and to contribute to improved clinical outcomes of cancer patients treated with immunotherapy.

Goals

See some of the most important goals for this research program.

read more

Research groups contributing to this research program

Computational immunology

Johannes Textor's research group studies the adaptive immune system, and its response to cancer, using computational tools such as simulations, machine learning algorithms, and artificial intelligence.

Experimental immunology

Annemiek van Spriel's research group studies the immune system at the cellular and molecular level. 

Genetic epidemiology

Sita Vermeulen's research group aims to understand underlying mechanisms of prognosis and treatment response in order to facilitate personalized medicine. The group mainly uses molecular epidemiological studies and has a focus on bladder cancer.

Spokesperson

dr. Kalijn Bol

contact form

Spokesperson

prof. dr. Jolanda de Vries

contact form